Live Breaking News & Updates on ஜேம்ஸ் கிஷுே

Stay updated with breaking news from ஜேம்ஸ் கிஷுே. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

James Xue , Privus Biologics , Singapore Health Sciences Authority , Mass Business Wire Canbridge Pharmaceuticals Inc , University Of Massachusetts Medical School Umass , Chinese National Medical Products Administration , Canbridge Pharmaceuticals Inc , Canbridge Pharmaceuticals Inc It , Pharmaceuticals Inc , Investigational New Drug , Health Sciences Authority , Wuxi Biologics , Paroxysmal Nocturnal Hemoglobinuria , Rare Diseases Diagnosis , Massachusetts Medical School , ஜேம்ஸ் கிஷுே , சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம் , கான்பிரிட்ஜ் மருந்துகள் இன்க் , மருந்துகள் இன்க் , ஆரோக்கியம் அறிவியல் அதிகாரம் , ரேர் நோய்கள் நோயறிதல் , மாசசூசெட்ஸ் மருத்துவ பள்ளி ,

CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation Mentor

To Provide Mentoring to Emerging Life Science Leaders in Rare Disease Support Termeer Foundation's Mission of Connecting Leaders to Catalyze New Treatments . ....

United States , Linkedin Termeerfoundation , James Xue , Henri Termeer , Belinda Termeer , China Alliance For Rare Disease , Research Development Association , Henri Termeer Network , Rd Committee Of China Pharmaceutical Innovation , Termeer Foundation Mentor , University Of Michigan Medical School , Umass Medical School , Shanghai Foundation For Rare Disease , Horae Gene Therapy Center , Canbridge Pharmaceuticals Inc , Termeer Foundation Mentors , Termeer Foundation , Canbridge Pharmaceuticals , Termeer Network , Emerging Life Science Leaders , Connecting Leaders , Catalyze New , Foundation Mentors , Henri Termeer Fellows , Founding Chair , Advisory Board ,

CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms

CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong Kong , University Of Massachusetts Medical School , United States , James Xue , Mass Business Wire Canbridge Pharmaceuticals Inc , Umass Medical School , Horae Gene Therapy Center , Canbridge Pharmaceuticals Inc , Logicbio Therapeutics Inc , Novel Liver Targeting Capsid , Support Development , Gene Therapy Programs , Exclusive License , Investigational Gene Editing Treatment , Methylmalonic Acidemia , Logicbio Therapeutics , Greater China , Massachusetts Medical School , Bio Therapeutics , Wuxi Biologics , Medical School , Pharmaceuticals Inc , ஹாங் காங் , பல்கலைக்கழகம் ஆஃப் மாசசூசெட்ஸ் மருத்துவ பள்ளி , ஒன்றுபட்டது மாநிலங்களில் , ஜேம்ஸ் கிஷுே ,

CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration

Press release content from Business Wire. The AP news staff was not involved in its creation.
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration
February 25, 2021 GMT
BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 25, 2021
CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing drug candidates in China and North Asia, and Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, have agreed to terminate their 2018 license agreement, in which Puma granted CANbridge exclusive rights to develop and commercialize NERLYNX® (neratinib) in Greater China, and to settle their arbitration related to the license agreement. ....

United States , Hong Kong , Pierre Fabre , James Xue , Puma Biotechnology Inc , Umass Medical School , Horae Gene Therapy Center , Canbridge Pharmaceuticals Inc , Planet Communications , North Asia , Puma Biotechnology , Greater China , Middle East , Positive Breast , Wuxi Biologics , Medical School , Pharmaceuticals Inc , Fetal Toxicity , Full Prescribing Information , Puma Patient Lynx , Business Wire , Products And Services , Diagnosis And Treatment , Licensing Agreements , Pharmaceutical Manufacturing , Health Care Industry ,

CANbridge Pharmaceuticals Appoints General Manager of China

Share:
CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it has appointed Justin Lu to the position of General Manager of China, responsible for setting up and operating commercial operations in China. Mr. Lu will be based in Shanghai.
Justin s proven expertise in pharmaceutical operations, developed over two decades at leading world-class companies, will allow CANbridge to build robust operations in China and carry us into the future as we grow our product portfolio, said James Xue, PhD, CANbridge Founder, Chairman and CEO. We are delighted to welcome him to the team. ....

Justin Lu , James Xue , Eli Lilly , Novartis Pharma , Umass Medical School , Shanghai Jiao Tong University School Of Medicine , Canbridge Pharmaceuticals Inc , Horae Gene Therapy Center , Pharmaceuticals Inc , General Manager , Rare Disease , Takeda Pharmaceutical , Celgene Pharmaceutical , Associate Marketing Manager , Senior Regional Sales Manager , Bayer Healthcare , Beijing Novartis , Medical Specialist , Clinical Medicine , Shanghai Jiao Tong University School , Wuxi Biologics , Medical School , Puma Biotechnology , ஜஸ்டின் லு , ஜேம்ஸ் கிஷுே , எலி லில்லி ,